抗CD19嵌合抗原受体T细胞所致淋巴瘤缓解与高血清白介素-15水平相关
在22例晚期淋巴瘤患者中开展临床试验,低剂量环磷酰胺联合氟达拉滨预处理后输注单剂抗CD19嵌合抗原受体T细胞,总缓解率73%、完全缓解55%、部分缓解18%;55%患者出现3或4级神经毒性且完全消退,高血清白介素-15水平与缓解及高血CAR+细胞峰值相关。
要点
- 22例晚期淋巴瘤患者接受低剂量化疗后单剂CAR-19 T细胞,总缓解率73%,完全缓解55%,部分缓解18%。
- 12例完全缓解中11例持续中;55%患者出现3或4级神经毒性且完全消退。
- 达缓解者血CAR+细胞峰值中位数98/μL,未达缓解者15/μL(P = .027)。
核心结论
- 低剂量化疗后输注CAR-19 T细胞可使晚期淋巴瘤缓解,高血清白介素-15水平与该方案有效性相关。
- 作者认为CAR-19 T细胞很可能成为复发淋巴瘤患者的重要治疗。
研究设计与样本
- 临床试验纳入22例晚期淋巴瘤患者,其中弥漫大B细胞淋巴瘤19例、滤泡性淋巴瘤2例、套细胞淋巴瘤1例。
- 患者接受低剂量环磷酰胺联合氟达拉滨预处理方案,2天后接受单剂CAR-19 T细胞输注。
主要发现
- 总缓解率为73%,其中完全缓解55%、部分缓解18%。
- 12例完全缓解中11例持续中。
- 55%患者出现3或4级神经毒性,且完全消退。
- 低剂量化疗预处理方案使外周血淋巴细胞减少并升高血清白介素-15。
- 达缓解者血CAR+细胞峰值中位数为98/μL,未达缓解者为15/μL(P = .027);高血清白介素-15水平与高血CAR+细胞峰值(P = .001)及淋巴瘤缓解(P < .001)相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 (CAR-19) have potent activity against acute lymphoblastic leukemia, but fewer results supporting treatment of lymphoma with CAR-19 T cells have been published. Patients with lymphoma that is chemotherapy refractory or relapsed after autologous stem-cell transplantation have a grim prognosis, and new treatments for these patients are clearly needed. Chemotherapy administered before adoptive T-cell transfer has been shown to enhance the antimalignancy activity of adoptively transferred T cells. Patients and Methods We treated 22 patients with advanced-stage lymphoma in a clinical trial of CAR-19 T cells preceded by low-dose chemotherapy. Nineteen patients had diffuse large B-cell lymphoma, two patients had follicular lymphoma, and one patient had mantle cell lymphoma. Patients received a single dose of CAR-19 T cells 2 days after a low-dose chemotherapy conditioning regimen of cyclophosphamide plus fludarabine. Results The overall remission rate was 73% with 55% complete remissions and 18% partial remissions. Eleven of 12 complete remissions are ongoing. Fifty-five percent of patients had grade 3 or 4 neurologic toxicities that completely resolved. The low-dose chemotherapy conditioning regimen depleted blood lymphocytes and increased serum interleukin-15 (IL-15). Patients who achieved a remission had a median peak blood CAR+ cell level of 98/μL and those who did not achieve a remission had a median peak blood CAR+ cell level of 15/μL ( P = .027). High serum IL-15 levels were associated with high peak blood CAR+ cell levels ( P = .001) and remissions of lymphoma ( P < .001). Conclusion CAR-19 T cells preceded by low-dose chemotherapy induced remission of advanced-stage lymphoma, and high serum IL-15 levels were associated with the effectiveness of this treatment regimen. CAR-19 T cells will likely become an important treatment for patients with relapsed lymphoma.
引用
- Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017. PMID: 28291388. doi:10.1200/JCO.2016.71.3024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。